Cart
sales@molnova.com
(E)-FeCP-oxindole
CAS No. 884338-18-5
(E)-FeCP-oxindole( —— )
Catalog No. M33847 CAS No. 884338-18-5
(E)-FeCP-oxindole is an inhibitor of VEGFR2 with IC50 of 214 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 102 | In Stock |
|
| 10MG | 154 | In Stock |
|
| 25MG | 258 | In Stock |
|
| 50MG | 359 | In Stock |
|
| 100MG | 488 | In Stock |
|
| 200MG | 643 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Name(E)-FeCP-oxindole
-
NoteResearch use only, not for human use.
-
Brief Description(E)-FeCP-oxindole is an inhibitor of VEGFR2 with IC50 of 214 nM.
-
Description(Z)-FeCP-oxindole is a selective human vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor with an IC50 value of 200 nM. (Z)-FeCP-oxindole can significantly inhibit VEGFR1 and PDGFRa or b at 10 μM. (Z)-FeCP-oxindole has some anticancer activity, acting on B16 murine melanoma lines with IC50 less than 1 μM.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetVEGFR
-
RecptorVEGFR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number884338-18-5
-
Formula Weight329.17
-
Molecular FormulaC19H15FeNO
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(\[C-]12[Fe+2]3456789([CH]1=[CH]3[CH]4=[CH]52)[CH-]%10[CH]6=[CH]7[CH]8=[CH]9%10)=C/%11\C=%12C(NC%11=O)=CC=CC%12
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
PAN-90806
PAN-90806 (CP-547632, CP547632) is a highly potent, ATP-competitive, orally active VEGFR-2 inhibitor that blocks VEGFR-2 kinase autophosphorylation (IC50=11 nM) and VEGF-induced VEGFR-2 phosphorylation (IC50=5 nM).
-
AMPK-IN-3
AMPK-IN-3 is a novel, selective and potent AMPK inhibitor with inhibitory effects on AMPK (α2), AMPK (α1) and KDR, with IC50 values of 60.7, 107 and 3820 nM, respectively.AMPK-IN-3 showed anticancer activity in K562 cells.
-
Lariciresinol
Lariciresinol is an enterolignan precursor, it possesses fungicidal activities by disrupting the fungal plasma membrane and therapeutic potential as a novel antifungal agent for the treatment of fungal infectious diseases in humans. Dietary lariciresinol can attenuate mammary tumor growth and reduce blood vessel density in human MCF-7 breast cancer xenografts and carcinogen-induced mammary tumors in rats.
